Serina Therapeutics Stock Price, News & Analysis

ser NYSE

Company Description

Welcome to the overview page for Serina Therapeutics (ser), where you can find comprehensive stock information and company updates.

Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.

Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-66.52%

Performance 1 year

$18.0M

Market Cap

10.7M

Shares outstanding

Latest News

View All

9 days ago

+5.99%

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

14 days ago

+2.98%

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

February 3, 2026

+1.47%

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

January 28, 2026

+30.15%

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease

clinical trial fda approval

January 15, 2026

+15.24%

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

December 11, 2025

-0.64%

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

SEC Filings

View All

February 17, 2026

[4] Serina Therapeutics (SER) awards 69,000 stock options to Chief Scientific Officer

February 17, 2026

[4] Serina Therapeutics (SER) SVP awarded 69,000 stock options at $2.76

February 17, 2026

[4] Director Simba Gill granted 92,000 Serina Therapeutics (SER) stock options

February 17, 2026

[4] Serina Therapeutics (SER) CEO awarded 230,100 new stock options

February 17, 2026

[EFFECT] Serina Therapeutics, Inc. SEC Filing

Insider Radar

View Form 4 Filings

Net Sellers

90-Day Summary

Shares Bought

58,500

Shares Sold

Transactions

Most Recent Transaction

Moreadith Randall (Chief Scientific Officer) sold 6,500 shares @ $3.03 on Feb 2, 2026

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

View Full Financials

$56K

Revenue (TTM)

-$11.1M

Net Income (TTM)

$-1.51

Diluted EPS (TTM)

-$17.1M

Operating Cash Flow

-19894.6%

Net Profit Margin

-30442.9%

Oper. Profit Margin

Upcoming Events

JUL

July 1, 2026 - September 30, 2026 Clinical

SMC review for Cohort 1

Blinded Safety Monitoring Committee review for SER-252 Phase 1b; enables advancement to Cohort 2

JUL

July 9, 2027 Regulatory

Deadline to regain NYSE compliance

End of 18-month cure period to regain NYSE American listing compliance; failure may trigger delisting.

Short Interest History

Last 12 Months

Loading short interest data...

Short interest in Serina Therapeutics (ser) currently stands at 1.0 million shares, up 1079.9% from the previous reporting period, representing 17.9% of the float. Over the past 12 months, short interest has increased by 3115.8%. This moderate level of short interest indicates notable bearish positioning.

Days to Cover History

Last 12 Months

Loading days to cover data...

Days to cover for Serina Therapeutics (ser) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 75.7% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 10.4 days.